Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD19-targetd CAR-T · 1 trial · 1 indication
The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).including the type, frequency and severity of adverse events
Disease improvement rate: The number of subjects who achieved disease improvement as a percentage of all subjects who received transfusions.
DOR will be assessed from the first assessment of remission to the first assessment of recurrence or progression of the disease or death from any cause
| Arm | Type | Description |
|---|---|---|
| CD19-targeted CAR-T | EXPERIMENTAL | The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B). |
| Name | Type | Description |
|---|---|---|
| CD19-targetd CAR-T | BIOLOGICAL | Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion |
Inclusion Criteria: 1. Age: ≥5 years and \<17 years old 2. To meet the diagnostic criteria of JDM, four or five of the following criteria must be met:① symmetrical proximal muscle weakness; ②Characteristic skin changes, including positive dermatitis (purplish red rash on upper eyelid with periorbit...
CD19-targeted CAR-T is an investigational cell therapy being studied for refractory Juvenile Dermatomyositis, a rare autoimmune disease in children. It is designed to target CD19-positive cells as part of the treatment approach. The therapy is currently in Phase 1 clinical development and is not yet approved for any use.
Precision BioSciences, Inc. (NASDAQ: DTIL) is developing CD19-targeted CAR-T. The company is conducting a Phase 1 clinical trial for this therapy in patients with refractory Juvenile Dermatomyositis. The trial is currently recruiting participants in China.
CD19-targeted CAR-T is in Phase 1 clinical development. It is an investigational therapy being studied for refractory Juvenile Dermatomyositis. The therapy is not yet approved by regulatory authorities and remains in the early stages of clinical testing.
CD19-targeted CAR-T is being evaluated in a Phase 1 clinical trial with the identifier NCT06569472. The trial is titled 'Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis' and is currently recruiting. It plans to enroll 10 participants aged 5 years and older in China.
CD19-targeted CAR-T is designed to target CD19, a protein found on the surface of certain immune cells. By targeting CD19-positive cells, the therapy aims to modulate the immune response in Juvenile Dermatomyositis. The exact mechanism is being studied in the ongoing Phase 1 clinical trial.